Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir

AIDS Research and Human Retroviruses

Volumn 29, Issue 2, 2013, Pages 235-241

  Martínez, Esteban ^a   D'albuquerque, Polyana M ^a   Pérez, Ignacio ^a   Pich, Judit ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BONE DENSITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872922748     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0150     Document Type: Article

References (24)

1. Vo TT, Ledergerber B, Keiser O, Hirschel B, Furrer H, Battegay M, et al.: Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008;197:1685-1694. (Pubitemid 351919632)
2. Gazzola L, Tincati C, and d'Arminio Monforte A: Noninfectious HIV-related comorbidities and HAART toxicities: Choosing alternative antiretroviral strategies. HIV Ther 2010; 5:553-565.
3. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-333.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011. Available at http://www .aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 25, 2012.
5. European AIDS Clinical Society Guidelines: Version 6-October 2011. Available at http://www.europeanaidsclinicalsociety .org/images/stories/EACS- Pdf/eacsguidelines-v6-english.pdf. Accessed May 25, 2012.
6. Panel De expertos De GESIDA y Plan Nacional sobre el Sida: National consensus document by GESIDA/National AIDS Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update). Enferm Infecc Microbiol Clin 2011;29:209.e1-103.
7. Moyle GJ and Back D: Principles and practice of HIVprotease inhibitor pharmacoenhancement. HIV Med 2001;2: 105-113. (Pubitemid 33114749)
8. The DAD Study Group: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356: 1723-1735.
9. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, et al.: Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41:898-905. (Pubitemid 27194157)
10. Shafran SD, Mashiter LD, and Roberts SE: The effect of lowdose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005;6:421-425. (Pubitemid 41723310)
11. Martinez E, Larrousse M, Llibre JM, Gutierrez F, Saumoy M, Antela A, et al.: Substitution of raltegravir for ritonavirboosted protease inhibitors in HIV-infected patients: The SPIRAL study. AIDS 2010;24:1697-1707.
12. Newcombe RG: Interval estimation for the difference between independent proportions: Comparison of eleven methods. StatMed 1998;17:873-890. (Pubitemid 28185166)
13. Martinez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, et al.: A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixeddose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009;51:290-297.
14. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al.: Simplification of antiretroviral therapy with tenofoviremtricitabine or abacavir-lamivudine: A randomized, 96-week trial. Clin Infect Dis 2009;49:1591-1601.
15. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al.: Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatmentnaive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806.
16. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al.: Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55:39-48.
17. Rockstroh JK, Lennox JL,Dejesus E, SaagMS, LazzarinA,Wan H, et al.: Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53:807-816.
18. Young B, Vanig T, Dejesus E, Hawkins T, St Clair M, Yau L, et al.: A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-nai?ve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials 2010;11:260-269.
19. Young B, Vanig T, Dejesus E, Hawkins T, St Clair M, Stancil B, et al.: 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-nai?ve HIV-1-infected patients: The SHIELD trial. HIV Clin Trials 2010;12:228-233.
20. Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, et al.: Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547-1556.
21. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al.: Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361:2230-2240.
22. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, et al.: Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55:49-57.
23. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al.: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-1678.
24. Bedimo R, Maalouf NM, Zhang S, Drechsler H, and Tebas P: Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012;26:825-831.